Phase II study of capecitabine, oxaliplatin and erlotinib in previously treated patients with metastatic colorectal cancer (MCRC)

Journal of Clinical Oncology ◽

10.1200/jco.2004.22.14_suppl.3580 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 3580-3580 ◽

Author(s):

J. A. Meyerhardt ◽

A. Xhu ◽

P. C. Enzinger ◽

D. P. Ryan ◽

J. W. Clark ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Previously Treated Patients ◽

Previously Treated

Download Full-text

Phase II study of capecitabine, oxaliplatin and erlotinib in previously treated patients with metastatic colorectal cancer (MCRC)

Journal of Clinical Oncology ◽

10.1200/jco.2004.22.90140.3580 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 3580-3580 ◽

Author(s):

J. A. Meyerhardt ◽

A. Xhu ◽

P. C. Enzinger ◽

D. P. Ryan ◽

J. W. Clark ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Previously Treated Patients ◽

Previously Treated

Download Full-text

A Phase II Study of Modified deGramont 5-Fluorouracil, Leucovorin, and Oxaliplatin in Previously Treated Patients with Metastatic Colorectal Cancer

Cancer Investigation ◽

10.1081/cnv-120022359 ◽

2003 ◽

Vol 21 (4) ◽

pp. 505-511 ◽

Author(s):

David P. Ryan ◽

Jeffrey W. Clark ◽

Matthew H. Kulke ◽

Charles S. Fuchs ◽

Craig C. Earle ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Previously Treated Patients ◽

Previously Treated

Download Full-text

Phase II Study of Weekly High Dose Fluorouracil in Previously Treated Patients with Metastatic Colorectal Cancer

Journal of Chemotherapy ◽

10.1179/joc.2000.12.2.183 ◽

2000 ◽

Vol 12 (2) ◽

pp. 183-185 ◽

Author(s):

W. Mermershtain ◽

K. Lavrenkov ◽

Y. Cohen

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

High Dose ◽

Previously Treated Patients ◽

Previously Treated

Download Full-text

Randomized phase II study of regorafenib followed by cetuximab versus reverse sequence for wild-type KRAS metastatic colorectal cancer previously treated with fluoropyrimidine, oxaliplatin, and irinotecan (REVERCE).

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.tps3662 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. TPS3662-TPS3662

Author(s):

Kohei Shitara ◽

Kentaro Yamazaki ◽

Hiroyuki Uetake ◽

Takeshi Kato ◽

Eiji Oki ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Wild Type ◽

Randomized Phase Ii ◽

Reverse Sequence ◽

Previously Treated

Download Full-text

Randomized phase II study of CPT-11 plus mitomycin C versus oxaliplatin plus mitomycin C in previously treated patients with advanced colorectal cancer (ACC)

European Journal of Cancer ◽

10.1016/s0959-8049(99)80658-3 ◽

1999 ◽

Vol 35 ◽

pp. S72-S73

Author(s):

H. Ulrich-Pur ◽

S. Brugger ◽

G.V. Kornek ◽

W. Fiebiger ◽

K. Haider ◽

...

Keyword(s):

Colorectal Cancer ◽

Mitomycin C ◽

Phase Ii ◽

Advanced Colorectal Cancer ◽

Phase Ii Study ◽

Randomized Phase Ii ◽

Previously Treated Patients ◽

Previously Treated

Download Full-text

A phase II study of dose-escalation of regorafenib for patients with previously treated metastatic colorectal cancer – DEREGULATE study - Trial in progress

Annals of Oncology ◽

10.1093/annonc/mdy151.291 ◽

2018 ◽

Vol 29 ◽

pp. v82

Author(s):

K. Kawaguchi ◽

R. Nishitai ◽

D. Manaka ◽

T. Ota ◽

Y. Nishikawa ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Dose Escalation ◽

Phase Ii Study ◽

Study Trial ◽

Previously Treated

Download Full-text

REVERCE: Randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for metastatic colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, and irinotecan—Biomarker analysis.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.3510 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. 3510-3510 ◽

Author(s):

Yasushi Tsuji ◽

Kohei Shitara ◽

Takeharu Yamanaka ◽

Tadamichi Denda ◽

Katsunori Shinozaki ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Phase Ii Study ◽

Randomized Phase Ii ◽

Biomarker Analysis ◽

Reverse Sequence ◽

Previously Treated ◽

Colorectal Cancer Patients

Download Full-text

P-272 Phase II study of Regorafenib as single agent for the treatment of patients with metastatic colorectal cancer with any RAS or BRAF mutation and previously treated with FOLFOXIRI plus bevacizumab

Annals of Oncology ◽

10.1093/annonc/mdv233.269 ◽

2015 ◽

Vol 26 ◽

pp. iv80

Author(s):

P. García Alfonso ◽

M.J. Ortiz ◽

G. Durán ◽

E. Falcó ◽

A. Muñoz ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Braf Mutation ◽

Phase Ii Study ◽

Single Agent ◽

Previously Treated

Download Full-text

Phase II study of bevacizumab and irinotecan as second-line therapy for patients with metastatic colorectal cancer previously treated with fluoropyrimidines, oxaliplatin, and bevacizumab

Cancer Chemotherapy and Pharmacology ◽

10.1007/s00280-017-3255-3 ◽

2017 ◽

Vol 79 (3) ◽

pp. 579-585 ◽

Author(s):

Hidekazu Kuramochi ◽

Masayuki Ando ◽

Michio Itabashi ◽

Go Nakajima ◽

Kazuyuki Kawakami ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Second Line ◽

Second Line Therapy ◽

Line Therapy ◽

Previously Treated

Download Full-text

Abstract CT124: A phase II study of bevacizumab and irinotecan as second-line therapy for patients with metastatic colorectal cancer previously treated with fluoropyrimidine, oxaliplatin, and bevacizumab

10.1158/1538-7445.am2016-ct124 ◽

2016 ◽

Author(s):

Go Nakajima ◽

Hidekazu Kuramochi ◽

Masayuki Ando ◽

Michio Itabashi ◽

Kazuyuki Kawakami ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Second Line ◽

Second Line Therapy ◽

Line Therapy ◽

Previously Treated

Download Full-text